FDA Approvals : Episode 5

Video

FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma

Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has granted an approval to brentuximab vedotin (Adcetris) in combination with adriamycin, vinblastine, and dacarbazine as a frontline treatment for patients with advanced classical Hodgkin lymphoma.

The decision is based on findings from the phase III ECHELON-1 trial, in which brentuximab vedotin plus AVD compared with standard ABVD, known as AVD plus bleomycin, demonstrated superior progression-free survival.

In the study, the brentuximab vedotin regimen reduced the risk of progression, death, or initiation of new therapy by 23% versus ABVD. The 2-year modified PFS rate was 82.1% with brentuximab vedotin compared with 77.25% for standard chemotherapy.

The FDA granted a breakthrough therapy designation for brentuximab vedotin in combination with chemotherapy for frontline advanced classical Hodgkin lymphoma in October 2017.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
Related Content